ScripWhile the world’s pharma industry has increasingly connected with Chinese-developed me-too or fast-follower novel drugs over the past few years, AstraZeneca, which already has more than three decades
ScripA little over two months into 2025 and two Chinese drug makers have reaped the successes of moving their first-in-class pipeline innovations onto the domestic market, while two others have encountered
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Novo Nordisk, IMMvention Collaboration
ScripVenture capital fundraising data show that $100m-plus mega-rounds continue to account for the vast majority of biopharmaceutical company VC financings, with overall investment in large rounds and indi